Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Patent
1995-06-06
1999-07-06
Minnifield, Nita
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
4241841, 4242771, 4242781, 424 851, 4241451, 424 852, 42419511, 4241981, 424450, 424 856, 4241551, 514 12, 530350, A61K 3900, A61K 4500, A61K 39385, A61K 4505
Patent
active
059194596
ABSTRACT:
The present invention encompasses methods for reducing or inhibiting growth factor in cancer cells and tissues. More particularly immunogenic growth factor-containing compositions are administered to a human or animal with a cancer or tumor. The immunogenic compositions elicit the production of antibodies specific for growth factor which reduce the level of circulating growth factor, thus reducing or eliminating the proliferation of cancer. The present invention encompasses growth factor-containing liposomes and vesicles having portions of growth factor externally presented on their surfaces. The present invention also includes antibodies specific for growth factor. Thus, according to the present invention, growth factor levels are reduced either by active immunization of an individual using immunogenic growth factor-containing compositions or by passive immunization via administering to the individual an antibody or a group of antibodies specific for growth factor.
REFERENCES:
patent: 4094971 (1978-06-01), Chedid et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4690915 (1987-09-01), Rosenbert et al.
patent: 4745051 (1988-05-01), Smith et al.
patent: 4777242 (1988-10-01), Nelles
patent: 4780313 (1988-10-01), Koichiro et al.
patent: 4806352 (1989-02-01), Cantrell
patent: 4879236 (1989-11-01), Smith et al.
patent: 4895835 (1990-01-01), Hasegawa
patent: 4963354 (1990-10-01), Shepard et al.
patent: 5030621 (1991-07-01), Bystryn
patent: 5194384 (1993-03-01), Bystryn
patent: 5409698 (1995-04-01), Anderson et al.
patent: 5650152 (1997-07-01), Anderson et al.
patent: 5665383 (1997-09-01), Grinstaff et al.
patent: 5681812 (1997-10-01), Coon et al.
patent: 5733876 (1998-03-01), O'Reilly et al.
Alving, C.R., et al., "Adjuvant Effects of Liposomes Containing Lipid A: Enhancement of Liposomal Antigen Presentation and Recruitment of Macrophages," Infection and Immunity, vol. 60, No. 6, pp. 2438-2444 (Jun. 1992).
Webb, N. R., et al., "Cell-surface Expression and Purification of Human CD4 Produced in Baculovirus-Infected Insect Cells," Proc. Natl. Acad. Sci., vol. 86, pp. 7731-7735 (Oct. 1989).
Verma, J.N., et al. "Adjuvant Effects of Liposomes Containing Lipid A: Enhancement of Liposomal Antigen Presentation and Recruitment of Macrophages," Infection and Immunity, vol. 60, No. 6, pp. 2438-2444 (Jun. 1992).
Sachs, L. "Growth, Differentiation and the Reversal of Malignancy," Scientific American, Jan. 1986, pp. 40-47.
Liotta, L.A., "Cancer Cell Invasion and Metastasis," Scientific American, Feb. 1992, pp. 54-63.
Feldman, M. and Eisenbach, L., "What Makes a Tumor Cell Metastatic?", Scientific American, Nov. 1988, pp. 60-85.
Haranaka, K., et al., "Role of Lipid A in the Production of Tumor Necrosis Factor and Differences in Antitumor Activity Between Tumor Necrosis Factor and Lipopolysaccharide," Tohoku J. exp. Med., 1984, pp. 385-396.
Costa, A., "Breast Cancer Chemoprevention," Eur J Cancer, vol. 29A No. 4, pp. 589-592 (1993).
Efferth, T. and Volm, M., "Antibody-Directed Therapy of Multidrug-Resistant Tumor Cells," Med. Oncol. & Tumor Pharmacother, vol. 9 No. 1, pp. 11-19 (1992).
Asano, T. and Kleinerman, E., "Liposome-Encapsulated MTP-PE: A Novel Biologic Agent for Cancer Therapy," Journal of Immunotherapy, 14: pp. 286-292 (1993).
Bartlett, G.R., "Phosphorus Assay in Column Chromatography", Scripps Clinic and Research Foundation, vol. 234, No. 3, pp. 466-468 (1959).
New, R.C., "Liposomes A Practical Approach", Practical Approach Series, pp. 105-107 (1990).
White, W.I. et al., "Antibody and Cytotoxic T-lymphocyte Responses to a Single Liposome-Associated Peptide Antigen", Vaccine, vol. 13, No. 12, pp. 1111-1122 (1995).
Fan, D. et al., "Antiproliferative Activity of Liposome-Encapsulated Transforming Growth Factor-.beta. against MDA-MB-435 Human Breast Carcinoma Cells", Cancer Communications, vol. 1, No. 6, pp. 337-343 (1989).
Youichi, Ishii et al., "Preparation of EGF Labeled Liposomes and Their Uptake by Hepatocytes", Biochemical and Biophysical Research Communications, vol. 160, No. 2, pp. 732-736 (1989).
Welch, Clin. Exp. Metastasis 15:272-306, 1997.
Mortarini et al. 1990 Int. J. Cancer 45: 334-41.
Munker et al. 1987 Cancer Res. 47: 4081-85.
Tubiana 1991. J. Cancer Res. Clin. Oncol. 117: 275-89.
Siemann.COPYRGT. 1987 In: Rodent Tumor Models in Exptal Cancer Therapy ed: Kallman pp. 12-15; Pergamon Press, NY.
Langer. 1990. Science 249: 1527-1533.
Bennett et al. 1992. J. Immunol Methods 153: 31-40.
Byars et al 1987 Vaccine 5: 223.
Warren et al 1988. CRC Critical Rev. in Immunol. 8(2):83-101.
Asano et al 1993. J. Immunotherap. 14:286-92.
Ozen. 1992 Current Opin. Oncol. 4/3:435-441.
Rose 1991. Sem. in Oncol. 18(6):536-542.
Breitmeyer et al 1990 Surg. Clin. North Am. 70/5:1081-1102.
Kohn et al 1993. Int. J. Cancer. 53:968-972.
Webb et al. 1989. Cell-surface expression and purification of human CD4 produced in baculovirus . . . PNAS 86: 7731-35.
Holaday John W.
Nacy Carol A.
Entremed, Inc.
Minnifield Nita
LandOfFree
Compositions and methods for treating cancer and hyperproliferat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating cancer and hyperproliferat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating cancer and hyperproliferat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-897307